• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Brands Reports Q1 2025 Financial Results

    10/10/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email

    Tilray Achieves 13% Year-Over-Year Growth, Generating Record Q1 Net Revenue of $200 Million

    Q1 Gross Margin Increases Over 500 Basis Points, Representing 20% Year-Over-Year Growth

    Tilray Beverages Achieves 132% Net Revenue Growth, Tilray Alternative Beverages Launched in October to Fuel Key U.S. Markets with Hemp-Derived Delta-9 THC Products

    German Medical Cannabis Flower Revenue Increases by 50% Following Legalization

    Conference Call to be Held at 8:30 a.m. ET Today

    NEW YORK and LEAMINGTON, Ontario, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company, today reported financial results for its first quarter ended August 31, 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

    Irwin D. Simon, Tilray Brands' Chairman and Chief Executive Officer, stated, "As the Chairman and CEO of Tilray Brands, I am excited to lead a company that is disrupting the CPG industry through innovative products that are transforming the way consumers eat, drink, and unwind with cannabis, hemp and beverage products. Our investments in the cannabis, wellness, beverage, and distribution industries are focused on shaping the future and staying ahead of the curve. We are dedicated to executing our strategic plan to increase revenue, drive operational efficiencies, and improve margins and profitability while investing in our continued growth. Our commitment to innovation and growth is unwavering."

    Mr. Simon, continued, "We believe that there is a greater likelihood that the upcoming U.S. Presidential elections will result in improved regulatory changes in the cannabis industry, as both candidates have publicly confirmed their support for further legalization. We are optimistic about the future of the cannabis industry and look forward to the potential opportunities that lie ahead."

    Financial Highlights – First Quarter Fiscal Year 2025

    • Net revenue increased 13% to $200 million in the first quarter compared to $177 million in the prior year quarter.
    • Gross profit increased by 35% to $59.7 million in the first quarter compared to $44.2 million in the prior year quarter. Gross margin increased to 30% in the first quarter compared to 25% in the prior year quarter.
    • Net loss improved by 38% to $(34.7) million in the first quarter compared to $(55.9) million in the prior year quarter.
    • Net loss per share improved to $(0.04) in the first quarter compared to $(0.10) in the prior year quarter.
    • Adjusted net loss per share improved to $(0.01) in the first quarter compared to $(0.04) in the prior year quarter.
    • Adjusted EBITDA in the first quarter was $9.3 million compared to $10.7 million in the prior year quarter.
    • Beverage alcohol net revenue including acquisitions increased 132% to $56.0 million in the first quarter.
      • Beverage alcohol gross margin was 41% in the first quarter.
    • Cannabis net revenue was $61.2 million in the first quarter.
      • Cannabis gross margin was 40% in the first quarter.
    • Distribution net revenue was $68.1 million in the first quarter.
      • Distribution gross margin was 12% in the first quarter.
    • Wellness net revenue increased 11% to $14.8 million in first the quarter.
      • Wellness gross margin was 32% in the first quarter.

    Live Conference Call and Audio Webcast

    Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. ET. Investors may join the live webcast available on the Investors section of the Company's website at www.tilray.com. A replay will be available and archived on the Company's website.

    About Tilray Brands

    Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

    For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

    For more information on Tilray Brands, visit www.Tilray.com and follow @Tilray

    Cautionary Statement Concerning Forward-Looking Statements

    Certain statements in this press release constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

    Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company's ability to disrupt the CPG industry for cannabis, hemp, and beverage consumption; the Company's ability to become a leading beverage alcohol Company; the Company's ability to achieve long term profitability; the Company's ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company's ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company's expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected commercial opportunities and regulatory developments in the U.S., including upon U.S. federal cannabis legalization or rescheduling; the Company's anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; the Company's ability to commercialize new and innovative products; market opportunities and regulatory risks for Hemp-Derived Delta-9 (HDD9) beverage products, and expected sales, distribution, margin, price and revenue generation projections; consumer sentiment regarding HDD9 beverage products; and Tilray's strategy and anticipated offerings within the HDD9 beverage product segment.

    Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

    Use of Non-U.S. GAAP Financial Measures

    This press release and the accompanying tables include non-GAAP financial measures, including Adjusted gross margin (consolidated and for each of our reporting segments), Adjusted gross profit (consolidated and for each of our reporting segments), Adjusted EBITDA, Adjusted net income (loss), Adjusted net income (loss) per share, free cash flow, adjusted free cash flow, constant currency presentations of revenue and cash and marketable securities. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

    Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.

    The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. A reconciliation of prior year revenue to constant currency revenue the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Adjusted EBITDA is calculated as net income (loss) before income tax benefits, net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; facility start-up and closure costs; litigation costs; restructuring costs, and transaction (income) costs, net. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Historically, we have included lease expenses for leases that were treated differently under IFRS 16 and ASC 842 in the calculation of adjusted EBITDA, aiming to align our definition with industry peers reporting under IFRS. The decision to include these lease expenses in the Company's definition of adjusted EBITDA was based on our efforts to maintain comparability with peers. However, as the Company has continued to diversify, particularly with strategic acquisitions such as the newly acquired beverage alcohol business portfolio, this comparison is no longer relevant, accordingly, we are no longer including this adjustment. Had the Company continued to include lease expenses that were treated differently under IFRS 16 and ASC 842, the impact to adjusted EBITDA would have been $0.7 million for the three months ended August 31, 2023.

    Adjusted net income (loss) is calculated as net loss attributable to stockholders of Tilray Brands, Inc., less; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; facility start-up and closure costs; litigation costs; restructuring costs and transaction (income) costs, net. A reconciliation of Adjusted net income (loss) to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release.

    Adjusted net income (loss) per share is calculated as net loss attributable to stockholders of Tilray Brands, Inc., net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; facility start-up and closure costs; litigation costs; restructuring costs and transaction (income) costs, divided by weighted average number of common shares outstanding. A reconciliation of Adjusted net income (loss) per share to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release. Adjusted net income (loss) per share is not calculated in accordance with GAAP and should not be considered an alternative for GAAP net income (loss) per share or as a measure of liquidity.

    Adjusted gross profit (consolidated and for each of our reporting segments), is calculated as gross profit adjusted to exclude the impact of purchase price accounting valuation step-up. A reconciliation of Adjusted gross profit, excluding purchase price accounting valuation step-up, to gross profit, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted gross margin (consolidated and for each of our reporting segments), excluding purchase price accounting valuation step-up, is calculated as revenue less cost of sales adjusted to add back amortization of inventory step-up, divided by revenue. A reconciliation of Adjusted gross margin, excluding purchase price accounting valuation step-up, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net, and the exclusion of growth CAPEX from investments in capital and intangible assets, net, which excludes the amount of capital expenditures that are considered to be associated with growth of future operations rather than to maintain the existing operations of the Company, and excludes our integration costs related to HEXO and the cash income taxes related to Aphria Diamond to align with management's prescribed guidance. A reconciliation of net cash flow provided by (used in) operating activities to adjusted free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

    Cash and marketable securities are comprised of two GAAP measures, cash and cash equivalents added to marketable securities. The Company's management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combing these two GAAP metrics.

    For further information:

    Media Contact: [email protected]

    Investor Contact: [email protected]



        
    Consolidated Statements of Financial Position   
     August 31, May 31,
    (in thousands of US dollars) 2024   2024 
    Assets   
    Current assets   
    Cash and cash equivalents$205,186  $228,340 
    Marketable securities 74,869   32,182 
    Accounts receivable, net 104,037   101,695 
    Inventory 264,295   252,087 
    Prepaids and other current assets 44,960   31,332 
    Assets held for sale 32,536   32,074 
    Total current assets 725,883   677,710 
    Capital assets 555,136   558,247 
    Operating lease, right-of-use assets 17,176   16,101 
    Intangible assets 908,768   915,469 
    Goodwill 2,009,714   2,008,884 
    Long-term investments 7,853   7,859 
    Convertible notes receivable 32,000   32,000 
    Other assets 5,337   5,395 
    Total assets$4,261,867  $4,221,665 
    Liabilities   
    Current liabilities   
    Bank indebtedness$18,134  $18,033 
    Accounts payable and accrued liabilities 236,146   241,957 
    Contingent consideration 15,000   15,000 
    Warrant liability 2,557   3,253 
    Current portion of lease liabilities 5,640   5,091 
    Current portion of long-term debt 16,072   15,506 
    Current portion of convertible debentures payable —   330 
    Total current liabilities 293,549   299,170 
    Long - term liabilities   
    Lease liabilities 60,657   60,422 
    Long-term debt 155,268   158,352 
    Convertible debentures payable 132,650   129,583 
    Deferred tax liabilities, net 136,230   130,870 
    Other liabilities 99   90 
    Total liabilities 778,453   778,487 
    Stockholders' equity   
    Common stock ($0.0001 par value; 1,198,000,000 common shares authorized; 875,444,828 and 831,925,373 common shares issued and outstanding, respectively) 88   83 
    Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively) —   — 
    Additional paid-in capital 6,217,533   6,146,810 
    Accumulated other comprehensive loss (39,877)  (43,499)
    Accumulated deficit (2,699,653)  (2,660,488)
    Total Tilray Brands, Inc. stockholders' equity 3,478,091   3,442,906 
    Non-controlling interests 5,323   272 
    Total stockholders' equity 3,483,414   3,443,178 
    Total liabilities and stockholders' equity$4,261,867  $4,221,665 
        



    Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

     For the three months ended    
     August 31, August 31, Change % Change
    (in thousands of U.S. dollars, except for per share data) 2024   2023  2024 vs. 2023
    Net revenue$200,044  $176,949  $23,095  13%
    Cost of goods sold 140,338   132,753   7,585  6%
    Gross profit 59,706   44,196   15,510  35%
    Operating expenses:       
    General and administrative 44,113   40,516   3,597  9%
    Selling 11,690   6,859   4,831  70%
    Amortization 21,804   22,225   (421) (2)%
    Marketing and promotion 11,566   8,535   3,031  36%
    Research and development 105   79   26  33%
    Change in fair value of contingent consideration —   (11,107)  11,107  (100)%
    Litigation costs, net of recoveries 1,595   2,034   (439) (22)%
    Restructuring costs 4,247   915   3,332  364%
    Transaction costs (income), net 1,156   8,502   (7,346) (86)%
    Total operating expenses 96,276   78,558   17,718  23%
    Operating loss (36,570)  (34,362)  (2,208) 6%
    Interest expense, net (9,842)  (9,835)  (7) 0%
    Non-operating income (expense), net 12,646   (4,402)  17,048  (387)%
    Loss before income taxes (33,766)  (48,599)  14,833  (31)%
    Income tax expense, net 886   7,264   (6,378) (88)%
    Net loss$(34,652) $(55,863) $21,211  (38)%
    Net loss per share - basic and diluted (0.04)  (0.10)  0.06  (60)%
            



    Condensed Consolidated Statements of Cash Flows       
     For the three months ended    
     August 31, August 31, Change % Change
    (in thousands of US dollars) 2024   2023  2024 vs. 2023
    Cash provided by (used in) operating activities:       
    Net loss$(34,652) $(55,863) $21,211  (38)%
    Adjustments for:       
    Deferred income tax expense, net 382   59   323  547%
    Unrealized foreign exchange (gain) loss (5,602)  (3,127)  (2,475) 79%
    Amortization 31,814   30,789   1,025  3%
    Accretion of convertible debt discount 3,067   5,544   (2,477) (45)%
    Other non-cash items 729   (6,357)  7,086  (111)%
    Stock-based compensation 6,917   8,257   (1,340) (16)%
    (Gain) loss on long-term investments & equity investments (499)  47   (546) (1162)%
    Loss on derivative instruments (696)  10,345   (11,041) (107)%
    Change in fair value of contingent consideration —   (11,107)  11,107  (100)%
    Change in non-cash working capital:       
    Accounts receivable (2,342)  13,044   (15,386) (118)%
    Prepaids and other current assets (13,570)  (4,654)  (8,916) 192%
    Inventory (12,383)  3,650   (16,033) (439)%
    Accounts payable and accrued liabilities (8,472)  (6,469)  (2,003) 31%
    Net cash used in operating activities (35,307)  (15,842)  (19,465) 123%
    Cash provided by (used in) investing activities:       
    Investment in capital and intangible assets (6,736)  (4,152)  (2,584) 62%
    Proceeds from disposal of capital and intangible assets 28   342   (314) (92)%
    Disposal (purchase) of marketable securities, net (42,687)  (45,436)  2,749  (6)%
    Business acquisitions, net of cash acquired —   22,956   (22,956) (100)%
    Net cash provided by (used in) investing activities (49,395)  (26,290)  (23,105) 88%
    Cash provided by (used in) financing activities:       
    Share capital issued, net of cash issuance costs 66,472   —   66,472  NM
    Proceeds from long-term debt —   7,621   (7,621) (100)%
    Repayment of long-term debt (4,791)  (6,369)  1,578  (25)%
    Proceeds from convertible debt —   21,553   (21,553) (100)%
    Repayment of convertible debt (330)  —   (330) NM
    Repayment of lease liabilities (862)  —   (862) NM
    Net increase (decrease) in bank indebtedness 101   (8,787)  8,888  (101)%
    Net cash provided by (used in) financing activities 60,590   14,018   46,572  332%
    Effect of foreign exchange on cash and cash equivalents 958   614   344  56%
    Net decrease in cash and cash equivalents (23,154)  (27,500)  4,346  (16)%
    Cash and cash equivalents, beginning of period 228,340   206,632   21,708  11%
    Cash and cash equivalents, end of period$205,186  $179,132  $26,054  15%
            



    Net Revenue by Operating Segment
     For the three months ended

     % of Total   For the three months ended    % of Total
    (In thousands of U.S. dollars)August 31, 2024 Revenue  August 31, 2023 Revenue
    Beverage alcohol business$55,972  28% $24,162  13%
    Cannabis business 61,249  31%  70,333  40%
    Distribution business 68,071  34%  69,157  39%
    Wellness business 14,752  7%  13,297  8%
    Total net revenue$200,044  100% $176,949  100%
            
    Net Revenue by Operating Segment in Constant Currency

            
     For the three months ended     For the three months ended    
     August 31, 2024   August 31, 2023  
    (In thousands of U.S. dollars)as reported in constant

    currency
     % of Total

    Revenue
     as reported in constant

    currency
     % of Total

    Revenue
    Beverage alcohol business$55,972  27% $24,162  13%
    Cannabis business 62,792  31%  70,333  40%
    Distribution business 70,396  35%  69,157  39%
    Wellness business 14,940  7%  13,297  8%
    Total net revenue$204,100  100% $176,949  100%
            
            
    Net Cannabis Revenue by Market Channel
     For the three months ended

     % of Total   For the three months ended

       % of Total
    (In thousands of U.S. dollars)August 31, 2024 Revenue  August 31, 2023 Revenue
    Revenue from Canadian medical cannabis$6,261  10% $6,142  9%
    Revenue from Canadian adult-use cannabis 57,235  94%  71,195  102%
    Revenue from wholesale cannabis 5,507  9%  5,295  7%
    Revenue from international cannabis 12,191  20%  14,252  20%
    Less excise taxes (19,945) (33)%  (26,551) (38)%
    Total$61,249  100% $70,333  100%
            
            
    Net Cannabis Revenue by Market Channel in Constant Currency

     For the three months ended

         For the three months ended

        
     August 31, 2024   August 31, 2023  
    (In thousands of U.S. dollars)as reported in constant

    currency
     % of Total

    Revenue
     as reported in constant

    currency
     % of Total

    Revenue
    Revenue from Canadian medical cannabis$6,432  10% $6,142  9%
    Revenue from Canadian adult-use cannabis 58,806  94%  71,195  102%
    Revenue from wholesale cannabis 5,658  9%  5,295  7%
    Revenue from international cannabis 12,388  20%  14,252  20%
    Less excise taxes (20,492) (33)%  (26,551) (38)%
    Total$62,792  100% $70,333  100%
            



    Other Financial Information: Key Operating Metrics   
     For the three months ended
     August 31, August 31,
    (in thousands of U.S. dollars) 2024   2023 
    Net beverage alcohol revenue$55,972  $24,162 
    Net cannabis revenue 61,249   70,333 
    Distribution revenue 68,071   69,157 
    Wellness revenue 14,752   13,297 
    Beverage alcohol costs 33,050   11,266 
    Cannabis costs 37,054   50,517 
    Distribution costs 60,138   61,468 
    Wellness costs 10,096   9,502 
    Adjusted gross profit (excluding PPA step-up) 59,881   49,302 
    Beverage alcohol adjusted gross margin (excluding PPA step-up) 41%  56%
    Cannabis adjusted gross margin (excluding PPA step-up) 40%  35%
    Distribution gross margin 12%  11%
    Wellness gross margin 32%  29%
    Adjusted EBITDA$9,334  $10,734 
    Cash and marketable securities as at the period ended: 280,055   466,465 
    Working capital as at the period ended:$432,334  $291,981 
        



    Other Financial Information: Gross Margin and Adjusted Gross Margin      
     For the three months ended August 31, 2024
    (In thousands of U.S. dollars)Beverage Cannabis Distribution Wellness Total
    Net revenue$55,972  $61,249  $68,071  $14,752  $200,044 
    Cost of goods sold 33,050   37,054   60,138   10,096   140,338 
    Gross profit 22,922   24,195   7,933   4,656   59,706 
    Gross margin 41%  40%  12%  32%  30%
    Adjustments:         
    Purchase price accounting step-up 175   —   —   —   175 
    Adjusted gross profit 23,097   24,195   7,933   4,656   59,881 
    Adjusted gross margin 41%  40%  12%  32%  30%
              
     For the three months ended August 31, 2023
    (In thousands of U.S. dollars)Beverage Cannabis Distribution Wellness Total
    Net revenue$24,162  $70,333  $69,157  $13,297  $176,949 
    Cost of goods sold 11,266   50,517   61,468   9,502   132,753 
    Gross profit 12,896   19,816   7,689   3,795   44,196 
    Gross margin 53%  28%  11%  29%  25%
    Adjustments:         
    Purchase price accounting step-up 590   4,516   —   —   5,106 
    Adjusted gross profit 13,486   24,332   7,689   3,795   49,302 
    Adjusted gross margin 56%  35%  11%  29%  28%
              



    Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization    
     For the three months ended    
     August 31, August 31, Change % Change
    (In thousands of U.S. dollars) 2024   2023  2024 vs. 2023
    Net loss$(34,652) $(55,863) $21,211  (38)%
    Income tax expense, net 886   7,264   (6,378) (88)%
    Interest expense, net 9,842   9,835   7  0%
    Non-operating income (expense), net (12,646)  4,402   (17,048) (387)%
    Amortization 31,814   30,789   1,025  3%
    Stock-based compensation 6,917   8,257   (1,340) (16)%
    Change in fair value of contingent consideration —   (11,107)  11,107  (100)%
    Purchase price accounting step-up 175   5,106   (4,931) (97)%
    Facility start-up and closure costs —   600   (600) (100)%
    Litigation costs, net of recoveries 1,595   2,034   (439) (22)%
    Restructuring costs 4,247   915   3,332  364%
    Transaction costs (income) 1,156   8,502   (7,346) (86)%
    Adjusted EBITDA$9,334  $10,734  $(1,400) (13)%
            
            
    Other Financial Information: Adjusted Net Loss and Adjusted Net Loss Per Share For the three months ended    
     August 31, August 31, Change % Change
      2024   2023  Change
    Net loss attributable to stockholders of Tilray Brands, Inc.$(39,165) $(71,525) $32,360  (45)%
    Non-operating income (expense), net (12,646)  4,402   (17,048) (387)%
    Amortization 31,814   30,789   1,025  3%
    Stock-based compensation 6,917   8,257   (1,340) (16)%
    Change in fair value of contingent consideration —   (11,107)  11,107  (100)%
    Facility start-up and closure costs —   600   (600) (100)%
    Litigation costs, net of recoveries 1,595   2,034   (439) (22)%
    Restructuring costs 4,247   915   3,332  364%
    Transaction costs (income) 1,156   8,502   (7,346) (86)%
    Adjusted net loss$(6,082) $(27,133) $21,051  (78)%
    Adjusted net loss per share - basic and diluted$(0.01) $(0.04) $0.03  (75)%
            
    Other Financial Information: Free Cash Flow
     For the three months ended    
     August 31, August 31, Change % Change
    (In thousands of U.S. dollars) 2024   2023  2024 vs. 2023
    Net cash used in operating activities$(35,307) $(15,842) $(19,465) 123%
    Less: investments in capital and intangible assets, net (6,708)  (3,810)  (2,898) 76%
    Free cash flow$(42,015) $(19,652) $(22,363) 114%
    Add: growth CAPEX 2,540   1,687   853  51%
    Add: cash income taxes related to Aphria Diamond —   5,714   (5,714) (100)%
    Add: integration costs related to HEXO —   5,915   (5,915) (100)%
    Adjusted free cash flow$(39,475) $(6,336) $(33,139) 523%


    Primary Logo

    Get the next $TLRY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Tilray Brands Inc.

      DEFA14A - Tilray Brands, Inc. (0001731348) (Filer)

      4/28/25 4:55:34 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Tilray Brands Inc.

      DEF 14A - Tilray Brands, Inc. (0001731348) (Filer)

      4/28/25 4:53:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      4/25/25 4:06:00 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    See more
    • Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

      ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

      1/23/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

      PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

      10/22/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Brewery Opens New Location in Fort Collins, Colorado

      FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

      8/5/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Financials

    Live finance-specific insights

    See more
    • Tilray Brands Reports Q3 Fiscal 2025 Financial Results

      Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

      4/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025

      NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, today announced that the Company will release financial results for its third quarter fiscal 2025 ended February 28, 2025 before financial markets open on April 8, 2025. Live Conference Call and Audio Webcast Tilray will hold a live conference call, which will be webcast, to discuss these results at 8:30 a.m. Eastern Time. The webcast can be accessed in the Investors section of Tilray's website at www.Tilray.com. About Tilray Bran

      3/27/25 4:30:00 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Reports Q2 2025 Financial Results

      Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net Revenue of $211 Million, 10% in Constant Currency Beverage Revenue Increase by 36%, International Cannabis by 25%, Wellness Segment by 13% Announces Project 420: A $25 Million Synergy Plan for Tilray Beverage Business Tilray Reaffirms Fiscal Year 2025 Guidance Conference Call to be Held at 8:30 a.m. ET Today NEW YORK and LEAMINGTON, Ontario, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods co

      1/10/25 7:00:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Faltischek Denise M bought $20,500 worth of shares (10,000 units at $2.05), increasing direct ownership by 4% to 293,269 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/18/24 8:32:10 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Gendel Mitchell bought $14,256 worth of shares (7,200 units at $1.98), increasing direct ownership by 4% to 195,796 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/16/24 1:07:47 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

      SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

      2/13/23 1:34:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Tilray Brands Inc.

      SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

      2/10/23 4:41:36 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Tilray Brands Inc.

      SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

      7/22/22 4:30:22 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Shock Top: A Bold Rebrand for a Craft Beer Icon

      PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ:TLRY, TSX:TLRY), known for its bold flavors and unfiltered wheat ales, today announced a transformative rebrand. With revamped packaging, a new logo, and an expanded, integrated marketing campaign, Shock Top aims to shock a new generation of beer drinkers with a modern look and shocking new seasonal flavors. Building on its legacy of delivering exceptional beers, Shock Top's rebrand introduces a completely new visual identity that enhances its personality and offers a unique experience with every flavor. The new Wedgehead icon is designed as a bolder and more cont

      5/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Co. Announces the Return of Delayed Pilsner

      PATCHOGUE, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Blue Point Brewing Co., a Tilray Brands, Inc., (NASDAQ:TLRY, TSX:TLRY) craft beer brand, announces the highly anticipated re-release of Delayed Pilsner, a beer crafted to soothe the soul of every New Yorker facing the inevitable delays of city life. Whether it's 2 minutes or 2 hours, delays are scientifically proven to be the bane of any New Yorker's existence. But fear not, Blue Point Brewing has brewed the ultimate lager to get you through this abomination. Delayed Pilsner is brewed with a blend of floral, spicy hops that impart subtle apple and lemon-lime aromas. Balanced by slight honey notes from a creamy malt body, the result is a

      5/6/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • 10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure

      BEND, Ore., April 30, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., (NASDAQ:TLRY, TSX:TLRY) craft beer brand, is excited to announce the launch of NA Apocalypse IPA, a non-alcoholic version of their beloved Apocalypse IPA. This new offering delivers the same bold, hop-driven flavor that fans have come to love, now without the alcohol. NA Apocalypse IPA is crafted with the same big flavor to provide the signature punch of pine, citrus, and tropical notes that define the original IPA, minus the alcohol. Whether you're winding down at the end of the day or gearing up for a new adventure, NA Apocalypse IPA offers a taste that's big on hops and light on compromise. "We

      4/30/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Alliance Global Partners reiterated coverage on Tilray with a new price target

      Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

      4/5/24 7:39:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Tilray with a new price target

      Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

      11/2/22 6:37:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray downgraded by The Benchmark Company with a new price target

      The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

      7/29/22 7:19:40 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Cohen Steven Michael

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/8/25 4:16:07 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Cohen Steven Michael claimed no ownership of stock in the company (SEC Form 3)

      3 - Tilray Brands, Inc. (0001731348) (Issuer)

      12/17/24 4:05:56 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care